miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression - Wikidata - awgldk - TriplyDB

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

http://www.wikidata.org/entity/Q24610377

about

MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics Nutrigenetics and Nutrimiromics of the Circadian System: The Time for Human Health Development of targeted therapies in treatment of glioblastoma Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients Developing epigenetic diagnostics and therapeutics for brain disorders Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid.MiR-221/222 target the DNA methyltransferase MGMT in glioma cells Unraveling 50-Year-Old Clues Linking Neurodegeneration and Cancer to Cycad Toxins: Are microRNAs Common Mediators?Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3 MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs.Identification of microRNAs associated with glioma diagnosis and prognosis.ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview.A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas.MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM.SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients.miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients.Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression.Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma.IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features.Maternal betaine supplementation during gestation modifies hippocampal expression of GR and its regulatory miRNAs in neonatal piglets Prioritizing cancer-related microRNAs by integrating microRNA and mRNA datasets.The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p Classifying lower grade glioma cases according to whole genome gene expression.MicroRNAs involved in chemo- and radioresistance of high-grade gliomas.Current progress for the use of miRNAs in glioblastoma treatment.MicroRNA biomarkers in glioblastoma.Circulating microRNA biomarkers for glioma and predicting response to therapy.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.MGMT testing--the challenges for biomarker-based glioma treatment.Predictive biomarkers investigated in glioblastoma.RAB34 was a progression- and prognosis-associated biomarker in gliomas.

P2860

Q26747273-0DF25C6D-61C8-4197-8977-0553C4595177 Q26765463-CD2A55B3-B9B8-4CE9-B16F-C19185A458C0 Q26778787-975F5924-F0A2-4B70-A16B-351F354BE265 Q26796590-F9AD49AA-0A18-4CC7-8366-67765A291C64 Q27022987-F5FFFAA8-6333-445F-A772-441DF1647431 Q27026117-9D2E1297-06AE-4480-89E7-CF1750C7EEBC Q27333913-B46528AC-4C5C-4C5F-B10C-9F5455C49878 Q28118866-DD987A11-0845-43B8-8CA8-27316A805382 Q28389159-A1164176-DE72-486D-9BF5-DFDE39BC1629 Q28389846-4504EC32-6F73-48CE-8D26-C87E1BA67B73 Q28658442-242C4CCE-A09E-4167-8206-E874D9C4CDBC Q30405560-263BF082-DC82-40D9-A51C-4F2375AE0166 Q33688677-FA1D435D-E46F-4552-9048-B0DE503A5EC8 Q33757037-9BD79902-7589-45D9-A5E7-E1230A1EE216 Q34409620-3EEDDAC9-6DCA-43B3-9253-40134B4F2765 Q34427825-496E0726-20DE-43B0-BCD9-53A556FDF46D Q34450679-BCC8FECC-F6F5-448B-9056-2CF1B8A6BAD0 Q34478948-352C56A5-556B-45AE-981E-C83F3FE1E218 Q35017237-4C8B050F-7266-4E30-AEAE-0FBD7E156A6C Q35121957-EC6B61F1-A6E5-4B1A-87BE-A477471C74C9 Q35132876-92363D90-437C-4B79-85F0-E14AC516C5FC Q35694536-28C41DE4-FE82-4597-B873-B85918D67A4A Q35792806-F3772588-F858-4A96-81EB-197A62853B58 Q35964266-E4BC1AB3-509F-499D-A79B-B377FB72B794 Q36562205-FAF916D8-4A08-4FD4-9109-6B84C9C91323 Q36627170-8B8AE611-DAEB-4802-B18F-6620ED8EC548 Q36648767-1A199AB5-493D-4B08-8736-0761357C5F19 Q36764848-91E247D6-9886-45B7-88A2-7B9CFC74269F Q37075791-5642EBF4-48F3-433B-AAA5-F2D95FE49D61 Q37335617-7384E048-E730-4E99-8CAE-4CB738E940EA Q37686691-113145A8-AA0E-4E99-B33A-1D53C0B35901 Q37687518-6DA22B12-AC4E-486A-BD53-3621B8A009C1 Q38097384-518C746F-B7BB-49C6-B82F-819EC467CF3B Q38102611-962E0CEF-78B4-4E58-B53E-25D5AD729A0F Q38108768-52B82A33-1C93-4A52-AAB7-C72625CE1EE7 Q38201683-DB5AEF00-262A-4720-A1C6-FE198C56A722 Q38203283-4D32AC7E-7DBA-43DA-9C46-E27DF24441D1 Q38218848-6E83BCB1-9869-4F96-9F55-E04ABA83FB17 Q38237337-2F8D3FD3-3AC5-41C8-B9D1-B6E07F967B26 Q38469088-D43AF49E-61B7-4133-AC21-3A81247CC2AB

P2860

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

http://www.wikidata.org/entity/Q24610377

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@ast

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@en

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@nl

type

label

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@ast

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@en

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@nl

prefLabel

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@ast

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@en

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@nl

P1433

Q24610377-7DF80FEB-D7CD-455B-9F38-6CF203094A97

P1476

Q24610377-2122BE4E-9EFA-44AC-9380-5A74766E25CE

P2093

Q24610377-1112105B-6F27-4EDD-ABC9-15B85B44E72D

Q24610377-1FEA8E8A-DC04-42B8-AF8E-55889B48CC1C

Q24610377-4900D182-0B47-4941-AE82-41FB355003AD

Q24610377-4D42D485-596B-4BB7-B7B9-508380C8EDFE

Q24610377-50389588-D405-42B0-8B82-E938E9755FCD

Q24610377-62275E85-3D33-483F-8892-6A0DCD0B97EE

Q24610377-73C5BC4F-5BB8-49B6-8E1D-3FB64E8E763D

Q24610377-7ED2232A-5F7A-4880-AC94-EF97DCF8CE63

Q24610377-938DF871-5FEA-4BC4-9B8D-4EE4657E0217

Q24610377-C058EC17-F299-474D-A9DA-8120A313101D

P2860

Q24610377-00792AA3-06A6-4E48-A8E0-395F0D0882B3

Q24610377-017319A3-4BDA-4B23-8F9E-34A40A53F9A1

Q24610377-04A55727-D9E3-4DC4-A94D-0473F64ECDD7

Q24610377-0BFD4D2E-4F17-4482-B512-24B48259CEF2

Q24610377-1760D513-D9F9-4F7D-B9B2-09531C0317DB

Q24610377-1AFA43BB-2C1F-4BCF-9524-96049D7821DA

Q24610377-1B5EB617-B1D3-4065-BFD2-FD21011196F7

Q24610377-23205ED2-EFF8-49A6-9C40-036670557E62

Q24610377-40E879D4-D65A-4E09-BAB8-18502B9251BB

Q24610377-604A7C6B-2C35-40FA-B584-2943B220218D

P304

Q24610377-46BCA267-6C96-437C-ACD9-66B85FF1605D

P31

Q24610377-3B946AF7-3915-46F4-AB13-1FE8CEAF2258

P3181

Q24610377-560A8BE9-7E67-463D-A337-6A665F3CE75D

P356

Q24610377-01A3A28A-1392-4BD6-BE81-BCAF4EEE6343

P407

Q24610377-F202A01B-7CB4-4E9F-9E12-A77111B906DF

P433

Q24610377-11CE3321-5BEA-40B4-9E4A-C7EB6C4F3FF9

P478

Q24610377-D858203E-0307-4503-88EC-D87A5A492491

P50

Q24610377-E49DDE80-1E73-4DF9-82FF-828E3485CBA8

P577

Q24610377-179279B1-D22B-4AE8-91A4-3CF7FA9E1E82

P5875

Q24610377-F651923F-CDA7-4E5F-8D46-69FA3D96181D

P698

Q24610377-7B3D4770-F1FD-4A9C-B713-A4D687750E04

P921

Q24610377-2DF7EA31-9A51-4892-A3CD-9F4DB3F02D25

P932

Q24610377-FBF68988-3E6A-478A-B8CA-71DAE64D93F5

P3181

P356

P1433

P1476

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

@en

P2093

Chuanlu Jiang

http://www.w3.org/2001/XMLSchema#string

Chunsheng Kang

http://www.w3.org/2001/XMLSchema#string

Clark C Chen

http://www.w3.org/2001/XMLSchema#string

Deepa Kushwaha

http://www.w3.org/2001/XMLSchema#string

Katherine Hoadley

http://www.w3.org/2001/XMLSchema#string

Shouwei Li

http://www.w3.org/2001/XMLSchema#string

Sonya Wei Song

http://www.w3.org/2001/XMLSchema#string

Tao Jiang

http://www.w3.org/2001/XMLSchema#string

Valya Ramakrishnan

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

miR-200 enhances mouse breast cancer cell colonization to form distant metastases

Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine

MicroRNA targeting specificity in mammals: determinants beyond seed pairing

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

MicroRNA signatures in human cancers

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

P304

712-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1330351

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/NEUONC/NOS089

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224926320

http://www.w3.org/2001/XMLSchema#string

P698

22570426

http://www.w3.org/2001/XMLSchema#string

P921

P932

3367855

http://www.w3.org/2001/XMLSchema#string